In vitro studies have demonstrated that mutations in ERCC3 impair DNA repair capability and confer a selective sensitivity to Irofulven, a sesquiterpene that has demonstrated some efficacy in clinical trials for metastatic PrCa [46]. Here, ERCC3 is linked to pure red-cell aplasia.